SEARCHSYSTEMATIC_REVIEWsystematic review, epidemiology

systematic_review·systematic review, epidemiology, public health, biomedical research, preclinical research·PMC10846678

Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard

Environmental Health Perspectives · 24 authors, 6 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

A systematic evidence map inventoried mammalian bioassay and epidemiological evidence for 345 PFAS, identifying 121 mammalian bioassay and 111 epidemiological studies that met screening criteria. Only 41 PFAS (roughly 11% of searched chemicals) had evidence across both mammalian bioassay and epidemiology data streams, revealing substantial data gaps across PFAS.

Full summary

624 CHARS

Systematic evidence map methods were used to search, screen, and inventory mammalian bioassay and epidemiological literature for 345 PFAS identified by the US EPA. More than 13,000 studies were identified, of which 121 mammalian bioassay and 111 epidemiological studies met screening criteria. Epidemiological evidence, available for 12 PFAS, most commonly assessed reproductive, endocrine, developmental, metabolic, cardiovascular, and immune outcomes. Overall, 41 PFAS had evidence across both data streams. No epidemiological and/or mammalian bioassay evidence were identified for most of the PFAS included in the search.

STUDY TYPE

systematic_review

SPECIALTY

systematic review

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10846678

Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard

Environmental Health Perspectives

READ THE FULL PAPER

ABSTRACT

Background: Per- and polyfluoroalkyl substances (PFAS) encompass a class of chemically and structurally diverse compounds that are extensively used in industry and detected in the environment. The US Environmental Protection Agency (US EPA) 2021 PFAS Strategic Roadmap describes national research plans to address the challenge of PFAS. Objectives: Systematic Evidence Map (SEM) methods were used to survey and summarize available epidemiological and mammalian bioassay evidence that could inform human health hazard identification for a set of 345 PFAS that were identified by the US EPA’s Center for Computational Toxicology and Exposure (CCTE) for in vitro toxicity and toxicokinetic assay testing and through interagency discussions on PFAS of interest. This work builds from the 2022 evidence map that collated evidence on a separate set of ∼ 150 PFAS. Like our previous work, this SEM does not include PFAS that are the subject of ongoing or completed assessments at the US EPA. Methods: SEM methods were used to search, screen, and inventory mammalian bioassay and epidemiological literature from peer-reviewed and gray literature sources using manual review and machine-learning software. For each included study, study design details and health end points examined were summarized in interactive web-based literature inventories. Some included studies also underwent study evaluation and detailed extraction of health end point data. All underlying data is publicly available online as interactive visuals with downloadable metadata. Results: More than 13,000 studies were identified from scientific databases. Screening processes identified 121 mammalian bioassay and 111 epidemiological studies that met screening criteria. Epidemiological evidence (available for 12 PFAS) mostly assessed the reproductive, endocrine, developmental, metabolic, cardiovascular, and immune systems. Mammalian bioassay evidence (available for 30 PFAS) commonly assessed effects in the reproductive, whole-body, nervous, and hepatic systems. Overall, 41 PFAS had evidence across mammalian bioassay and epidemiology data streams (roughly 11% of searched chemicals). Discussion: No epidemiological and/or mammalian bioassay evidence were identified for most of the PFAS included in our search. Results from this SEM, our 2022 SEM on ∼ 150 PFAS, and other PFAS assessment products from the US EPA are compiled into a comprehensive PFAS dashboard that provides researchers and regulators an overview of the current PFAS human health landscape including data gaps and can serve as a scoping tool to facilitate prioritization of PFAS-related research and/or risk assessment activities. https://doi.org/10.1289/EHP13423

CITATION EXPORT

Avanti V. Shirke, Elizabeth G. Radke, Cynthia Lin et al.. Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard. Environmental Health Perspectives. (2024). https://doi.org/10.1289/EHP13423

AUTHORS

24 · 6 CENTRES

Avanti V. Shirke, Elizabeth G. Radke, Cynthia Lin, Robyn Blain, Nicole Vetter, Courtney Lemeris, Pamela Hartman, Heidi Hubbard, Michelle Angrish, Xabier Arzuaga, Johanna Congleton, Allen Davis, Laura V. Dishaw, Ryan Jones, Richard Judson, J. Phillip Kaiser, Andrew Kraft, Lucina Lizarraga, Pamela D. Noyes, Grace Patlewicz, Michele Taylor, Antony J. Williams, Kristina A. Thayer, Laura M. Carlson

1Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), US Environmental Protection Agency (US EPA), Washington, DC, USA
2ICF International, Fairfax, Virginia, USA
3CPAD, US EPA, Durham, North Carolina, USA
4Center for Public Health and Environmental Assessment, Health & Environmental Effects Assessment Division (HEEAD), US EPA, Durham, North Carolina, USA
5Center for Computational Toxicology and Exposure (CCTE), US EPA, Durham, North Carolina, USA
6CPAD, US EPA, Cincinnati, Ohio, USA